Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Cost-Effectiveness Analysis of Pharmacotherapy for Hematemesis-Melena Treatment in Hospitalized Patients with Hepatic Cirrhosis

The Indonesian Biomedical Journal · Vol. 5 No. 1 (2013) · hlm. 43–43

DOI
10.18585/inabj.v5i1.50
ISSN
2085-3297, 2355-9179
Terbit
2013-04-01
Penerbit
Secretariat of The Indonesian Biomedical Journal
Bahasa
en
Lisensi
creativecommons.org/licenses/by-nc/4.0/

Abstrak

BACKGROUND: Acute variceal haemorrhage is a complication of cirrhosis that can be life threatening. It is a pharmacist’s duty to ensure therapeutic and pharmaceutical care which is not only safe and effective for the patient but also is cost-effective in order to attain improvement of the patient’s quality of life. Therefore, pharmacoeconomic evaluation especially cost-effectiveness analysis (CEA), which compares costs and consequences of drug therapy, is needed. This study was aimed to evaluate the therapeutic cost-effectiveness of hematemesis-melena treatment in hepatic cirrhotic patients.METHODS: A total of 42 patients receiving vitamin K and vitamin K-transamin were studied retrospectively from patients’ medical records in 2 years and analyzed with cost-effectiveness grid and average cost-effectiveness ratio (ACER) based on Child-Turcotte-Pugh (CTP) Score.RESULTS: Cost-effectiveness grid was dominant for vitamin K in patients with CTP Score A. ACER analysis showed a lower score for vitamin K in all patients included CTP Score classification. There was no significant difference in duration of cessation of bleeding treatment in patients with vitamin K compared with vitamin K-transamin in patients with CTP Score A and B, while significant difference was found in patients with CTP Score C.CONCLUSION: Vitamin K appeared to be more cost effective as compared with vitamin K-transamin in all patients. The use of vitamin K had greater benefit than the combination with transamin in all patients and CTP Score classification, and thus should be considered as a primary therapy. Therefore, transamin addition as an alternative therapy for hepatic cirrhosis patients with hematemesis-melena should be considered.KEYWORDS: CEA, cost-effectiveness analysis, child-turcotte-pugh score, hepatic cirrhosis, hematemesismelena, vitamin K, transamin

Kata kunci

Jaringan kolaborasi para penulis

28 penulis · 58 tautan kepenulisan bersama · 17 lintas organisasi

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • University of Surabaya
  • Universitas Airlangga
  • Universitas Gadjah Mada
  • Petra Christian University
  • University of Brawijaya
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Rivan Virlando SuryadinataUniversity of Surabaya12
Marthy Meliana Ariyanti JalmavPetra Christian University4
Zahwa DhibaUniversity of Surabaya3
Siska Rian PratiwiUniversity of Surabaya2
Ananta YudiarsoUniversity of Surabaya2
Rizkia ArrahmahUniversity of Surabaya2
Siti Saharah AbdullahAfiliasi tidak diketahui2
Reza Dwi AnggrealdiUniversity of Surabaya2
I Nyoman Yoga DiputraUniversity of Surabaya2
- SuyantoAfiliasi tidak diketahui1
Pandu LaksonoUniversity of Surabaya1
Heru WijonoUniversity of Surabaya1
Pande Made Ayu ApriantiUniversity of Surabaya1
Angela Nofvianti Cahyo WatiUniversity of Surabaya1
Putri Aisyah RachmatianiUniversity of Surabaya1
Jeffri ArisandiUniversity of Brawijaya1
Abdul RahemUniversitas Airlangga1
Richa RatnasariUniversity of Surabaya1
Anugrah Putri ApriliaUniversity of Surabaya1
Zullies IkawatiUniversitas Gadjah Mada1
Tri Murti AndayaniUniversitas Gadjah Mada1
Daniel MaranathaUniversitas Airlangga1
Mariana WahyudiUniversity of Surabaya1
Suyanto SuyantoAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S2764892910, pertama di-harvest 19 Nov 2026, terakhir terlihat 19 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">Cost-Effectiveness Analysis of Pharmacotherapy for Hematemesis-Melena Treatment in Hospitalized Patients with Hepatic Cirrhosis</dc:title><dc:creator>Doddy de Queljoe</dc:creator><dc:creator>Amelia Lorensia</dc:creator><dc:creator>Liana Widharta</dc:creator><dc:creator>Sugiarto Widjaja</dc:creator><dc:subject>cost-effectiveness</dc:subject><dc:subject>liver cirrhosis</dc:subject><dc:subject>variceal bleeding</dc:subject><dc:subject>vitamin K</dc:subject><dc:subject>Child-Pugh score</dc:subject><dc:subject>drug therapy costs</dc:subject><dc:description xml:lang="en">BACKGROUND: Acute variceal haemorrhage is a complication of cirrhosis that can be life threatening. It is a pharmacist’s duty to ensure therapeutic and pharmaceutical care which is not only safe and effective for the patient but also is cost-effective in order to attain improvement of the patient’s quality of life. Therefore, pharmacoeconomic evaluation especially cost-effectiveness analysis (CEA), which compares costs and consequences of drug therapy, is needed. This study was aimed to evaluate the therapeutic cost-effectiveness of hematemesis-melena treatment in hepatic cirrhotic patients.METHODS: A total of 42 patients receiving vitamin K and vitamin K-transamin were studied retrospectively from patients’ medical records in 2 years and analyzed with cost-effectiveness grid and average cost-effectiveness ratio (ACER) based on Child-Turcotte-Pugh (CTP) Score.RESULTS: Cost-effectiveness grid was dominant for vitamin K in patients with CTP Score A. ACER analysis showed a lower score for vitamin K in all patients included CTP Score classification. There was no significant difference in duration of cessation of bleeding treatment in patients with vitamin K compared with vitamin K-transamin in patients with CTP Score A and B, while significant difference was found in patients with CTP Score C.CONCLUSION: Vitamin K appeared to be more cost effective as compared with vitamin K-transamin in all patients. The use of vitamin K had greater benefit than the combination with transamin in all patients and CTP Score classification, and thus should be considered as a primary therapy. Therefore, transamin addition as an alternative therapy for hepatic cirrhosis patients with hematemesis-melena should be considered.KEYWORDS: CEA, cost-effectiveness analysis, child-turcotte-pugh score, hepatic cirrhosis, hematemesismelena, vitamin K, transamin</dc:description><dc:publisher>Secretariat of The Indonesian Biomedical Journal</dc:publisher><dc:date>2013-04-01</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.18585/inabj.v5i1.50</dc:identifier><dc:identifier>10.18585/inabj.v5i1.50</dc:identifier><dc:source>The Indonesian Biomedical Journal; Vol 5 No 1 (2013); 43-43</dc:source><dc:source>2085-3297</dc:source><dc:source>2355-9179</dc:source><dc:language>en</dc:language><dc:relation>https://inabj.org/index.php/ibj/article/download/50/216</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc/4.0/</dc:rights></oai_dc:dc>